Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374868
Status:
COMPLETED
Last Update Posted:
2010-11-04
First Post:
2006-09-11
Brief Title:
Pemetrexed Plus Cisplatin Bi-Weekly in Patients With Urothelial Cancer Metastatic Locally Advanced or Non-Resectable
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase 12 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally Advanced Non-Resectable or Metastatic Urothelial Cancer
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the anti-tumor activity as measured by response rate to bi-weekly pemetrexed plus cisplatin in chemo-naive patients with diagnosed metastatic or locally advanced non-resectable urothelial cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-ES-S085 | OTHER | Eli Lilly and Company | None |